In vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kB activation in HL-60 cells

Acta Pharmacologica Sinica

Volumn 30, Issue 1, 2009, Pages 131-140

  Li, Min ^a   Sun, Wan ^a   Yang, Ya Ping ^a   Xu, Bo ^a   Yi, Wen Yuan ^a   Ma, Yan Xia ^a   Li, Zhong Jun ^b   Cui, Jing Rong ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anticancer; Apoptosis; HL 60; NF kB; Thalidomide

Indexed keywords

1 O METHYL 2,3,4 TRIACETYL 6 TETRAFLUOROPHTHALIMIDO 6 DEOXY ALPHA DEXTRO GLUCOPYRANOSE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; STA 35; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; 1 O METHYL 2,3,4 TRI ACETYL 6 TETRAFLUOROPHTHALIMIDO 6 DEOXY D GLUCOPYRANOSE; 1-O-METHYL-2,3,4-TRI-ACETYL-6-TETRAFLUOROPHTHALIMIDO-6-DEOXY-D-GLUCOPYRANOSE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUCOSIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN HEK293; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO SELECTION; PROTEIN EXPRESSION; ANIMAL; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; METABOLISM; NEOPLASM; REPORTER GENE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; GENES, REPORTER; GLUCOSIDES; HL-60 CELLS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64849110248     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2008.13     Document Type: Article

References (36)

1. Sen R, Baltimore D. Inducibility of kappa immunoglubin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-8.
2. Olivier S, Robe P, Bours V. Can NF-κB be a target for novel and effcient anti-cancer agents? Biochem Pharmacol 2006; 72: 1054- 68.
3. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276: 22382-7.
4. Um JH, Kang CD, Lee BG, Kim DW, Chung BS, Kim SH. Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance. Oncogene 2001; 20: 6048-56.
5. Wu JT, Kral JG. The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005; 123: 158-69.
6. Hales BF. Talidomide on the comeback trail. Nat Med 1999; 5: 489-90.
7. Hashimoto Y. Novel biological response modifiers derived from thalidomide. Curr Med Chem 1998; 5:163-78.
8. Hashimoto Y. Structure development of biological response modifiers based on thalidomide. Bioorg Med Chem 2002; 10: 461-79.
9. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802-11.
10. Miyachi H, Azuma A, Ogasawara A, Uchimura E, Watanabe N, Kobayashi Y, et al. Novel biological respoonse modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity. J Med Chem 1997; 40: 2858-65.
11. Miyachi H, Ogasawara A, Azuma A, Hashimoto Y. Tumor necrosis factor-alpha production-inhibiting activity of phthalimide analogues on human leukemia THP-1 cells and a structure-activity relationship study. Bioorg Med Chem 1997; 5: 2095-102.
12. Sou S, Mayumi S, Takahashim H, Yamasaki R, Kadoya S, Sodeoka M, et al. Novel alpha-glucosidase inhibitors with a tetrachloro-phthalimide skeleton. Bioorg Med Chem Lett 2000; 10: 1081-4.
13. Sou S, Takahashi H, Yamasaki R, Kagechika H, Endo Y, Hashimoto Y. Alpha-glucosidase inhibitors with a 4,5,6,7-tetrachlorophtha-limide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group. Chem Pharm Bull 2001; 49: 791-3.
14. Noguchi T, Shimazawa R, Nagasawa K, Hashimoto Y. Thalidomide and its analogues as cyclooxygenase inhibitors. Bioorg Med Chem Lett 2002; 12: 1043-6.
15. Sano H, Noguchi T, Tanatani A, Miyachi H, Hashimoto Y. N-phenylphthalimide-type cyclooxygenase (COX) inhibitors derived from thalidomide: substituent effects on subtype selectivity. Chem Pharm Bull 2004; 52: 1021-2.
16. Noguchi T, Sano H, Shimazawa R, Tanatani A, Miyachi H, Hashimoto Y. Phenylhomophthlimide-type NOS inhibitors derived from thalidomide. Bioorg Med Chem Lett 2004; 14: 4141-5.
17. Shimazawa R, Sano H, Tanatani A, Miyachi H, Hashimoto Y. Talidomide as a nitric oxide synthase inhibitor and its structural development. Chem Pharm Bull 2004; 52: 498-9.
18. Inatsuki S, Noguchi T, Miyachi H, Oda S, Iguchi T, Kizaki M, et al. Tubulin-polymerization inhibitors derived from thalidomide. Bioorg Med Chem Lett 2005; 15: 321-5.
19. Toe SK. Properties of thalidomide and its analogues: implication for anticancer therapy. AAP S J 2005; 7: E14-19.
20. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, et al. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 2006; 12: 5526-32.
21. Capitosti SM, Hansen TP, Brown ML. Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer. Bioorg Med Chem 2004; 12: 327-36.
22. Lindhorst TK (2000) (eds). Essentials of carbohydrate chemistry and biochemistry. Wiley-VCH, Weinheim; p72.
23. Ng SSW, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, et al. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 2003; 63: 3189-94.
24. Zhang SN, Li ZJ, Cai MS. Synthesis of N-sugar-substituted phthalimides and their derivatives from sugar azides and phthalicanhydride. Carbohydr Res 2004; 339: 1419-20.
25. Ma YX, Fu HZ, Li M, Sun W, Xu B, Cui JR. An anticacer effect of a new saponin component from Gymnoladus chinensis Baillon through inactivation of nuclear factor-kappaB. Anti-cancer Drugs 2007; 18: 41-6.
26. Xu MJ, Cui JR, Fu HZ, Proksch P, Lin WH, Li M. Embelin derivatives, and their anticancer activity through microtubule disassembly. Planta Med 2005; 71: 944-8.
27. Kochlatyi S, Gibbons N, Matana J. Extracellular matrix oxidation modulates survival, NF-κB translocation, and MAPK activity in mesangial cells. Exp Mol Pathol 2002; 73: 191-7.
28. Sen S, D'Incalci M. Apotosis. biochemical events and relevance cancer chemotherapy. FEBS Lett 1992; 307: 122-7.
29. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, et al. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 2007; 26: 1166-77.
30. Kanegae Y, Tavares AT, Belmonte JCI, Verma IM. Role of Rel/ NF-kappaB transcription factors during the outgrowth of the vertebrate limb. Nature 1998; 392: 611-4.
31. Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, et al. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retro-viruses 1997; 13: 857-63.
32. Du GJ, Lin HH, Xu QT, Wang MW. Talidomide inhibits growth of tumors through COX-2 degradation independent of anti angio-genesis. Vascul Pharmacol 2005; 2: 112-9.
33. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-8.
34. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-81.
35. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-50.
36. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immuno-modulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-30.